secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-12-30T23:59:59+00:00
Accession:  0001193125-25-337099
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx completes rolling BLA submission for DTX401 gene therapy to FDA for GSDIa
--------------------------------------------------------------------------------

- BLA submission for DTX401 (pariglasgene brecaparvovec) completed for glycogen storage disease type Ia; based on 52 treated patients with up to 6 years follow-up.
- Phase 3 GlucoGene study showed significant reductions in daily cornstarch intake while maintaining euglycemia and improved quality of life.
- Rolling review began with non-clinical/clinical modules in August 2025; CMC module now submitted to complete the package.
- DTX401 was well tolerated with an acceptable safety profile per the press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525337099/0001193125-25-337099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525337099/rare-20251230.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-337099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer